In a pivotal shift for the management of deficient mismatch repair/microsatellite-high (dMMR/MSI-H) colorectal cancer (CRC), new research presented at the American Society of Clinical Oncology (ASCO) annual meeting suggests that patients who achieve a clinical complete response (cCR) to immunotherapy may safely forgo long-term maintenance therapy. The findings, which challenge the current practice of prolonged PD-1 inhibitor administration, indicate that active surveillance offers comparable survival outcomes with a significant reduction in toxic side effects.
The Paradigm Shift: Main Facts and Findings
For years, the standard approach to dMMR/MSI-H colorectal cancer has been evolving toward "organ-preservation strategies"—efforts to avoid the morbidity of radical surgery by utilizing immune checkpoint inhibitors. While these agents have proven remarkably effective at inducing complete responses, the duration of therapy required to maintain that response has remained a subject of intense debate.
According to data presented by Xiaohang Gao, MD, of Sun Yat-sen University Cancer Center, the results from a prospective cohort study involving 129 patients indicate that "less is more." After a median follow-up of more than three years, patients who transitioned to a surveillance-only model following a confirmed cCR experienced a disease-free survival (DFS) rate of 96.4%. This was statistically comparable to the 98.2% DFS observed in patients who continued maintenance pembrolizumab (Keytruda) for three years.
Even more striking were the overall survival (OS) figures. Every patient in the observation group remained alive at the three-year mark, while 98.4% of those who continued maintenance therapy survived. These figures demonstrate that the aggressive approach of continuing therapy provides no clear survival benefit over a strategy of "watchful waiting" once a complete clinical response is achieved.
Chronology: A Multi-Year Prospective Investigation
The journey to these findings began in 2018 and spanned through 2025, involving a collaborative effort across five major medical centers in China. Researchers tracked 318 patients diagnosed with dMMR/MSI-H CRC who were treated with pembrolizumab.
The study’s timeline for patient stratification was rigorous:
- 2018–2025: Enrollment and follow-up of 318 patients.
- Initial Response Phase: Of the cohort, 195 patients achieved a clinical complete response (cCR) using PD-1 inhibitors.
- Selection Phase: After excluding patients who opted for surgical intervention and those who did not meet the criteria for cCR, 129 patients were selected for the comparative study.
- Intervention Phase: Patients were divided into two cohorts: one entering immediate observation and one continuing maintenance therapy for up to 36 months.
- Assessment: cCR was defined through a combination of endoscopy and imaging, with 80 patients undergoing biopsy to confirm the absence of residual tumor.
The demographic profile of the participants underscored the clinical significance of the study, with a median age of 48, suggesting that these findings are particularly relevant for younger patients who are highly motivated to preserve their organs and avoid the life-altering impacts of bowel surgery.
Supporting Data: The Burden of Toxicity
While the survival statistics were the primary endpoint, the secondary data regarding toxicity—specifically immune-related adverse events (irAEs)—provided the most compelling argument for treatment discontinuation.
The study revealed a stark contrast in the quality of life for the two groups. While both groups experienced irAEs at similar rates (62.1% in the observation group versus 66.7% in the maintenance group), the timing and severity of these events were vastly different.
In the maintenance group, the burden of toxicity intensified significantly post-cCR. The rate of new-onset or worsening irAEs was 30.2% for those continuing therapy, compared to a negligible 1.5% in the observation group (P<0.001). Furthermore, Grade 3 or higher adverse events—which can lead to treatment discontinuation, hospitalizations, and long-term organ damage—occurred in 4.8% of the maintenance patients, compared to 0% in the observation cohort.
Common adverse events reported across both groups included thyroid dysfunction, elevated liver transaminases, and dermatological issues such as rash and pruritus. The data suggests that by stopping immunotherapy after achieving a complete response, clinicians can spare patients from these cumulative, and often debilitating, toxicities.
Official Responses and Clinical Perspectives
The medical community has reacted with cautious optimism. Filippo Pietrantonio, MD, of the National Cancer Institute in Milan, Italy, served as the invited discussant at the ASCO meeting. He lauded the study for its attempt to provide clarity in an area currently driven more by clinical intuition than by randomized trial data.
"The study shows that observation after cCR was not associated with a clear loss in terms of disease-free survival, potentially reducing toxicity and cost," Dr. Pietrantonio stated. However, he emphasized that the field must remain prudent. "Non-operative management should probably be conducted within the framework of clinical trials," he cautioned, noting that the study, while impactful, does not replace the need for randomized, large-scale prospective trials to standardize the "gold standard" of care.
Dr. Gao herself acknowledged the inherent limitations of the study, noting the non-randomized design and the heterogeneity in the types of PD-1 inhibitors used across the five participating centers. Despite these limitations, she remains confident in the study’s primary message: "PD-1 inhibitor therapy induced cCR in 60% of patients, supporting non-operative management as a feasible organ-preservation strategy."
Implications for Future Practice
The implications of this study are profound for the oncology community. Currently, clinical guidelines for rectal cancer have already integrated non-operative management, but the landscape for colon cancer remains less settled.
1. Reassessing the "Maintenance" Dogma
The findings suggest that the clinical community may be overtreating patients. If a patient reaches a complete response, the risk of unnecessary, long-term immunotherapy may outweigh the perceived benefit of "locking in" that response. The study supports the discontinuation of therapy after cCR, provided there is a rigorous surveillance protocol, particularly within the first two years of follow-up.
2. The Rise of Surveillance Strategies
For patients, the prospect of surveillance is often preferred over both surgery and long-term drug therapy. However, the success of this strategy relies on high-quality imaging and endoscopic monitoring. As noted by Dr. Pietrantonio, the medical field must now work to define the "optimal approach to observation," including how often patients should be screened and what markers—such as circulating tumor DNA (ctDNA)—should be used to detect potential recurrences early.
3. Economic and Quality-of-Life Considerations
Beyond survival, the reduction of healthcare costs is a major consideration. PD-1 inhibitors are among the most expensive therapies in the oncology armamentarium. By shortening the duration of treatment without compromising oncologic outcomes, this strategy could significantly lower the financial burden on healthcare systems and individual patients, while simultaneously improving the quality of life by avoiding chronic immune-related side effects.
Conclusion: A Path Forward
The research from the Sun Yat-sen University Cancer Center marks a turning point in the management of dMMR/MSI-H colorectal cancer. It provides a robust evidence base for the safety of treatment de-escalation, a concept that is gaining traction across multiple solid tumor types.
While the medical community waits for further prospective randomized validation, the current data offers a clear mandate: clinicians should carefully consider the balance between the benefits of continued therapy and the risk of cumulative toxicity. For the patient, this transition from active treatment to active surveillance represents a move toward a more personalized, less invasive, and more sustainable future in cancer care. As the field moves forward, the focus will likely shift toward refining the surveillance protocols and identifying biological predictors that can tell us with certainty which patients can safely stop treatment and which, if any, require further intervention.
